Skip to main content

Psychedelic Treatments

Numinus Wellness and global contract research organization Syreon Corp. announced this week that “significant progress” has been made on their compassionate access trial on the use of psilocybin-assisted motivational enhancement therapy to treat substance use disorders.
MDMA-assisted psychotherapy for the treatment of alcohol use disorder was found to improve psychosocial functioning with no unexpected adverse events in a clinical trial conducted by London-based Awakn Life Sciences.
With the approval of psychedelic medicines imminent, the Psychiatry & Behavioral Health Learning Network (PBHLN) has announced that its inaugural Sana Symposium will take place Sept. 17-19, 2021.
Psychedelic medicine biotech firm MindMed has announced it has begun a study for a technology that could shorten and stop the effects of an LSD trip during therapy, which could create an “emergency shut-off switch” for psychedelic-assisted therapy.
The Multidisciplinary Association for Psychedelic Studies (MAPS) and Fireside Project, a not-for-profit psychedelic support services organization, announced plans to launch a national support line to help individuals having difficult psychedelic experiences and those who want to gain a better understanding of past psychedelic experiences.
With the approval of psychedelic medicines imminent, the Psychiatry & Behavioral Health Learning Network (PBHLN) has announced that its inaugural Sana Symposium will take place Sept. 17-19, 2021.
Back to Top